Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical and Nevro Preliminary Full-Year 2024 Revenue Outlook: On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year ...

Buying $100 In GMED: If an investor had bought $100 of GMED stock 10 years ago, it would be worth $356.36 today based on a price of $86.88 for GMED at the time of writing.

Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share.

Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

Globus Medical has a 12 month low of $49.33 and a 12 month high of $94.93. Globus Medical ( NYSE:GMED – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 5th.